(Q34420818)

2 August 2017

Linezolid for the treatment of multidrug-resistant tuberculosis (English)

1 reference

2 August 2017

0 references

multiple drug resistance

1 reference

1 reference

Jesús Fortún

1

1 reference

2 August 2017

Pilar Martín-Dávila

2

1 reference

2 August 2017

Enrique Navas

3

1 reference

2 August 2017

Ma Jesús Pérez-Elías

4

1 reference

2 August 2017

Javier Cobo

5

1 reference

2 August 2017

Marta Tato

6

1 reference

2 August 2017

Elia Gómez-G De la Pedrosa

7

1 reference

2 August 2017

Enrique Gómez-Mampaso

8

1 reference

2 August 2017

Santiago Moreno

9

1 reference

2 August 2017

language of work or name

English

0 references

publication date

23 May 2005

1 reference

Journal of Antimicrobial Chemotherapy

2 August 2017

1 reference

2 August 2017

56

1 reference

2 August 2017

1

1 reference

2 August 2017

180-185

1 reference

In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method

2 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

A multicenter evaluation of linezolid antimicrobial activity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Activities of linezolid against rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Safety and tolerability of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Hematologic effects of linezolid: summary of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Mechanisms for linezolid-induced anemia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Causal relationship between neuropathy and prolonged linezolid use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid-associated peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid-induced pure red blood cell aplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid and reversible myelosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

21 January 2018

Linezolid-induced anemia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

Linezolid-induced lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKI148

21 January 2018

Identifiers

DOI

10.1093/JAC/DKI148

1 reference

2 August 2017

1 reference